Periconceptional Folic Acid Supplementation and Infant Risk of Congenital Heart Defects inNorway 1999–2009

Authors:

Abstract
Background: The birth prevalence of congenital heart defects (CHDs) has decreased inCanada and Europe. Recommended intake of folic acid in pregnancy is a suggestive risk‐reducing factor forCHDs. We investigated the association between periconceptional intake of folic acid supplements and infant risk ofCHDs.Methods: Information on maternal intake of folic acid supplements before and during pregnancy in the Medical Birth Registry ofNorway 1999–2009 was updated with information onCHDdiagnoses from national health registers and the Cardiovascular Diseases inNorway Project. The association between folic acid intake and infant risk ofCHDwas estimated as relative risk (RR) with binomial log linear regression.Results: Among 517 784 non‐chromosomal singleton births, 6200 children were identified withCHDand 1153 with severeCHD. For all births, 18.4% of the mothers initiated folic acid supplements before pregnancy and 31.6% during pregnancy. The adjustedRRfor severeCHDwas 0.99 [95% confidence interval [CI] 0.86, 1.13] comparing periconceptional intake of folic acid with no intake. Specifically,RRfor conotruncal defects was 0.99 [95%CI0.80, 1.22], atrioventricular septal defects 1.19 [95%CI0.78, 1.81], left ventricular outflow tract obstructions 1.02 [95%CI0.78, 1.32], and right ventricular outflow tract obstructions 0.97 [95%CI0.72, 1.29]. Birth prevalence of septal defects was higher in the group exposed to folic acid supplements withRR1.19 [95%CI1.10, 1.30].Conclusions: Periconceptional folic acid supplement use showed no association with severe CHDs in the newborn. An unexpected association with an increased risk of septal defects warrants further investigation.
Funding Information
  • Norges Forskningsråd (190858/V50)

This publication has 24 references indexed in Scilit: